Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ivabradine - film-coated tablet - 5 milligram(s) - other cardiac preparations; ivabradine

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ivabradine - film-coated tablet - 7.5 milligram(s) - other cardiac preparations; ivabradine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - ivabradine hydrochloride 5,39 mg - eq. ivabradine 5 mg - film-coated tablet - 5 mg - ivabradine hydrochloride 5.39 mg - ivabradine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - ivabradine hydrochloride 8,085 mg - eq. ivabradine 7,5 mg - film-coated tablet - 7,5 mg - ivabradine hydrochloride 8.085 mg - ivabradine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - ivabradine hydrochloride 5,39 mg - eq. ivabradine 5 mg - film-coated tablet - 5 mg - ivabradine hydrochloride 5.39 mg - ivabradine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - ivabradine hydrochloride 8,085 mg - eq. ivabradine 7,5 mg - film-coated tablet - 7,5 mg - ivabradine hydrochloride 8.085 mg - ivabradine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ivabradine oxalate 5,961 mg - eq. ivabradine 5 mg - film-coated tablet - 5 mg - ivabradine oxalate 5.961 mg - ivabradine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ivabradine oxalate 8,941 mg - eq. ivabradine 7,5 mg - film-coated tablet - 7,5 mg - ivabradine oxalate 8.941 mg - ivabradine

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - acalabrutinib, quantity: 100 mg - capsule, hard - excipient ingredients: iron oxide yellow; indigo carmine aluminium lake; pregelatinised starch; sodium starch glycollate type a; gelatin; shellac; silicified microcrystalline cellulose; propylene glycol; titanium dioxide; iron oxide black; magnesium stearate - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.,calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia(cll)/small lymphocytic lymphoma (sll).

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - acalabrutinib maleate monohydrate, quantity: 129 mg - tablet, film coated - excipient ingredients: mannitol; microcrystalline cellulose; hyprolose; sodium stearylfumarate; hypromellose; copovidone; titanium dioxide; macrogol 3350; medium chain triglycerides; iron oxide yellow; iron oxide red - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.,this indication is approved via the provisional approval pathway, based on overall response rate. full registration for this indication depends on verification and description of clinical benefit in confirmatory trials. calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll).